12:00 AM
 | 
Sep 03, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Trastuzumab emtansine regulatory update

Genentech submitted a BLA to FDA for T-DM1 to treat HER2-positive, unresectable locally advanced or metastatic breast cancer who have received prior treatment with Herceptin trastuzumab and a taxane chemotherapy. The Roche unit said it also plans to open an Expanded Access Program in the U.S. to provide T-DM1 to patients with HER2-positive...

Read the full 254 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >